Covista: A Mispriced Bet On The Healthcare Worker Shortage

Walden University delivered 27% revenue growth and 13% enrollment growth, offsetting Chamberlain University's 1% enrollment decline; Covista is trading materially below its intrinsic value despite these short-term headwinds. Key risks are heavy reliance on Title IV funding and potential regulatory changes, while long-term healthcare demand and AI-driven career shifts provide structural growth support and limit downside.

Analysis

The structural winner is the asset-light, online-first arm of the business (Walden-style delivery) and vendors that enable scale — learning platforms, simulation/supervised-practice marketplaces, and clinical placement coordinators. Those second-order beneficiaries capture margin upside as instructional delivery shifts from labor-intensive cohorts to automated, AI-augmented pathways; expect SG&A as a share of revenue to fall materially over a 12–36 month window if execution holds.

Regulatory tail risk is concentrated and binary: a Title IV eligibility hit or accelerated regulatory scrutiny can compress multiples sharply and remove access to the low-cost capital channel that funds student acquisition. That outcome can happen inside a quarter if new rules or enforcement guidance lands, but absent such a shock the secular healthcare staffing shortage and employer-driven reskilling create a multi-year demand runway that limits downside.

Near-term catalysts to watch are enrollment trajectory by campus and program (Chamberlain vs Walden cohorts), DoE commentary on Title IV policy, and margin inflection points driven by AI initiatives (automation of tutoring/grading/placement) over the next 3–12 months. Consensus underestimates the optionality from AI-enabled unit economics improvement: even modest efficiency gains (5–8% EBITDA expansion) imply a re-rate because the business is highly recurring. The largest single reversing force would be a regulatory funding change or negative cohort quality metrics disclosed in a single quarter that materially reduce perceived lifetime value of students.

Key Decisions for Investors

• Long Grand Canyon Education (LOPE) — buy into any 5–10% pullback, target +25–35% TSR over 9–12 months driven by enrollment resilience and pricing power; size 0.5–1.0% NAV and hedge with 9–12 month 20–25% OTM puts to cap tail risk (downside ~20–30% if funding shock occurs).
• Structured long on Adtalem (ATGE) via 12–18 month call spread (buy ATM LEAP, sell ~40% OTM) to express secular healthcare-education re-rate with defined premium loss; expect 2.5–4x payoff if margins expand 5–10% within 12–24 months, max loss = premium paid.
• Relative-value pair: long LOPE / short Chegg (CHGG) equal notional for 6–12 months — rationale: LOPE captures degree/reskilling demand and Title IV stability, CHGG faces secular risk from AI-driven commoditization of textbook/support services; target 20%+ relative outperformance, unwind on convergence or if macro student-attendance data flips.
• If Covista is available publicly or via debt, buy 12–24 month call exposure (or the equity) sized 0.5% NAV as a convex, outcome-dependent wager; hedge with broad education-sector puts or sell a small portion into any favorable headline to trim entry risk.